FDA approves Depomed PHN drug
The once daily tablet, Gralise is developed by Depomed and it is licensed to Abbott Products in US, Mexico and Canada. Depomed CEO Carl Pelzel said the approval
South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology.